AbbVie and Brise reveal migraine pact for two preclinical programs worth up to $757 million
- AbbVie and Brise Pharmaceuticals have disclosed an agreement covering two preclinical migraine programs.
- Potential aggregate deal value is up to US$757 million, plus royalties on future sales.
- Brise leads discovery work, while AbbVie handles global development and commercialization.
- Brise reports having already hit several near-term milestones; the milestones achieved, the payments and any upfront amount were not disclosed.
💡 Points Based on public reports
Up to $757M sounds large, but for two preclinical programs it is mostly milestone paper, and the undisclosed upfront is the number that tells you AbbVie's conviction. Why disclose a 2024 deal only now? Migraine is crowded with CGRP agents, so the novelty of Brise's mechanism is what to watch, plus any IND timing.
AbbVie, Brise disclose deal for two preclinical migraine meds ↗